Teleflex Incorporated (TFX) Raised to “Outperform” at Leerink Swann
Teleflex Incorporated (NYSE:TFX) was upgraded by equities researchers at Leerink Swann from a “market perform” rating to an “outperform” rating in a research note issued on Thursday, The Fly reports.
A number of other brokerages have also weighed in on TFX. Zacks Investment Research upgraded shares of Teleflex from a “hold” rating to a “buy” rating and set a $228.00 price target on the stock in a report on Friday, June 23rd. BidaskClub lowered shares of Teleflex from a “hold” rating to a “sell” rating in a report on Tuesday, August 8th. Needham & Company LLC reiterated a “buy” rating on shares of Teleflex in a report on Friday, August 4th. Jefferies Group LLC reiterated a “buy” rating and issued a $253.00 price target (up previously from $230.00) on shares of Teleflex in a report on Wednesday, August 9th. Finally, Deutsche Bank AG reiterated a “buy” rating and issued a $238.00 price target (up previously from $220.00) on shares of Teleflex in a report on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. Teleflex presently has an average rating of “Buy” and a consensus target price of $237.00.
Shares of Teleflex (TFX) traded up 0.77% during mid-day trading on Thursday, reaching $227.14. The company’s stock had a trading volume of 363,964 shares. The company has a market capitalization of $10.23 billion, a price-to-earnings ratio of 43.44 and a beta of 1.05. Teleflex has a 1-year low of $136.53 and a 1-year high of $228.83. The firm’s 50 day moving average price is $210.65 and its 200-day moving average price is $202.16.
Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $2.04 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.91 by $0.13. The company had revenue of $528.60 million for the quarter, compared to analyst estimates of $518.98 million. Teleflex had a net margin of 12.36% and a return on equity of 16.12%. Teleflex’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter last year, the business earned $1.89 EPS. On average, analysts predict that Teleflex will post $8.28 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Teleflex Incorporated (TFX) Raised to “Outperform” at Leerink Swann” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/07/teleflex-incorporated-tfx-raised-to-outperform-at-leerink-swann.html.
In other Teleflex news, Director Gretchen R. Haggerty bought 1,000 shares of the business’s stock in a transaction dated Wednesday, June 21st. The shares were acquired at an average price of $203.82 per share, with a total value of $203,820.00. Following the purchase, the director now owns 1,760 shares in the company, valued at approximately $358,723.20. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Stephen K. M.D. Klasko sold 200 shares of the firm’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $211.75, for a total transaction of $42,350.00. Following the completion of the transaction, the director now directly owns 8,080 shares in the company, valued at approximately $1,710,940. The disclosure for this sale can be found here. In the last three months, insiders sold 600 shares of company stock worth $125,652. Insiders own 2.39% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Toronto Dominion Bank raised its stake in shares of Teleflex by 14.5% in the 2nd quarter. Toronto Dominion Bank now owns 552 shares of the medical technology company’s stock valued at $115,000 after acquiring an additional 70 shares during the period. Asset Planning Services Ltd. purchased a new position in shares of Teleflex in the 1st quarter valued at $116,000. Tower Research Capital LLC TRC purchased a new position in shares of Teleflex in the 2nd quarter valued at $118,000. Livforsakringsbolaget Skandia Omsesidigt purchased a new position in shares of Teleflex in the 1st quarter valued at $155,000. Finally, Huntington National Bank raised its stake in shares of Teleflex by 6.5% in the 2nd quarter. Huntington National Bank now owns 820 shares of the medical technology company’s stock valued at $145,000 after acquiring an additional 50 shares during the period. 90.50% of the stock is currently owned by institutional investors and hedge funds.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.